DXB 1.28% 7.7¢ dimerix limited

I think I remember someone asking DXB about patients who had...

  1. 2,656 Posts.
    lightbulb Created with Sketch. 435
    I think I remember someone asking DXB about patients who had remained on DMX-200 & that they weren’t continuing to monitor them. There wasn’t a great number, so it probably wouldn’t be too hard to look at, but no doubt this would be an ethics issue and have to be included within the trial for longer term data collection. Hopefully these patients continue to benefit in kidney health.

    This could have been beneficial for longer term data, so maybe this will happen post Ph2 in into Ph3? IDK?

    We are almost in June & my guess is we will get an update when both trials are fully recruited & dosed after run in period. Quality over quantity in trial patients will be all important in a smaller Ph2. The last thing we want is non compliant trial patients on top of the reasonably stringent inclusion/exclusion criteria affecting data.

    We have some really decent trial sites, in the public & private sector, not worried about that. If it’s going to take a little longer than expected for a better outcome in choosing suitable trial patients, so be it. We are dealing with human beings with health issues & lives to live also outside appointments & trial obligations. Best wishes to all
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
(20min delay)
Mkt cap ! $12.22M
Open High Low Value Volume
7.7¢ 7.7¢ 7.7¢ $15.75K 204.5K

Buyers (Bids)

No. Vol. Price($)
1 50000 7.6¢

Sellers (Offers)

Price($) Vol. No.
7.7¢ 5727 1
View Market Depth
Last update - 15.48pm 17/06/2019 (20 minute delay) ?
-0.001 ( 2.67 %)
Open High Low Volume
7.6¢ 7.7¢ 7.6¢ 23965
Last updated 15.43pm 17/06/2019 (live) ?
DXB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.